Company intelligence / Profile preview

Schorter

New York City, New York, United Statesfr.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Schrödinger provides industry-leading computational platforms for molecular design and drug discovery. Its technology accelerates the simulation and modeling of molecules at atomic resolution to improve efficiency in developing new drugs and materials. The company's software has contributed to successful clinical candidates through partnerships with major pharmaceutical firms such as Bayer and Takeda. Notably, Nimbus Therapeutics—co-founded by Schrödinger—advanced an Acetyl-CoA carboxylase inhibitor into late-stage clinical trials for non-alcoholic steatohepatitis.

Modalities: Small moleculeBiologicPeptidesAntibody
Industry: Drug Discovery Services

Partnerships

BayerTakedaNimbus Therapeutics (co-founder)

Beyond the preview

Go deeper on Schorter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schorter.

Explore the full profile